- Home
- SD vs KALV Comparison
SD vs KALV Comparison
Compare SD & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SD
- KALV
- Stock Information
- Founded
- SD 2006
- KALV N/A
- Country
- SD United States
- KALV United States
- Employees
- SD N/A
- KALV N/A
- Industry
- SD Oil & Gas Production
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- SD Energy
- KALV Health Care
- Exchange
- SD Nasdaq
- KALV Nasdaq
- Market Cap
- SD 420.5M
- KALV 418.1M
- IPO Year
- SD 2007
- KALV N/A
- Fundamental
- Price
- SD $10.55
- KALV $8.36
- Analyst Decision
- SD
- KALV Strong Buy
- Analyst Count
- SD 0
- KALV 6
- Target Price
- SD N/A
- KALV $26.25
- AVG Volume (30 Days)
- SD 332.6K
- KALV 421.6K
- Earning Date
- SD 11-06-2024
- KALV 12-31-2024
- Dividend Yield
- SD 4.18%
- KALV N/A
- EPS Growth
- SD N/A
- KALV N/A
- EPS
- SD 1.27
- KALV N/A
- Revenue
- SD $120,243,000.00
- KALV N/A
- Revenue This Year
- SD N/A
- KALV N/A
- Revenue Next Year
- SD $43.19
- KALV N/A
- P/E Ratio
- SD $8.29
- KALV N/A
- Revenue Growth
- SD N/A
- KALV N/A
- 52 Week Low
- SD $10.31
- KALV $7.98
- 52 Week High
- SD $15.31
- KALV $16.88
- Technical
- Relative Strength Index (RSI)
- SD 32.11
- KALV 36.75
- Support Level
- SD $10.31
- KALV $8.48
- Resistance Level
- SD $11.10
- KALV $9.30
- Average True Range (ATR)
- SD 0.32
- KALV 0.65
- MACD
- SD -0.09
- KALV -0.06
- Stochastic Oscillator
- SD 16.22
- KALV 17.12
About SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.